Matthew Leoni

1.2k total citations
27 papers, 931 citations indexed

About

Matthew Leoni is a scholar working on Neurology, Epidemiology and Dermatology. According to data from OpenAlex, Matthew Leoni has authored 27 papers receiving a total of 931 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Neurology, 10 papers in Epidemiology and 9 papers in Dermatology. Recurrent topics in Matthew Leoni's work include Acne and Rosacea Treatments and Effects (9 papers), Herpesvirus Infections and Treatments (8 papers) and Parkinson's Disease Mechanisms and Treatments (5 papers). Matthew Leoni is often cited by papers focused on Acne and Rosacea Treatments and Effects (9 papers), Herpesvirus Infections and Treatments (8 papers) and Parkinson's Disease Mechanisms and Treatments (5 papers). Matthew Leoni collaborates with scholars based in United States, France and Canada. Matthew Leoni's co-authors include Douglas H. Smith, Xiaohan Chen, Masahiro Nonaka, Angela Moore, Jerry Tan, Joseph F. Fowler, Kappa P. Meadows, Tracy K. McIntosh, Martin Steinhoff and Michael Jarratt and has published in prestigious journals such as The Lancet, Blood and Neurology.

In The Last Decade

Matthew Leoni

25 papers receiving 893 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew Leoni United States	14	418	292	250	177	138	27	931
Andrea Carlin Italy	17	32 0.1×	93 0.3×	32 0.1×	149 0.8×	178 1.3×	32	853
Marie‐Bénédicte Rougier France	23	47 0.1×	129 0.4×	103 0.4×	317 1.8×	35 0.3×	102	1.7k
Caroline Perner United States	10	83 0.2×	37 0.1×	87 0.3×	170 1.0×	20 0.1×	13	641
Jula Huppert Germany	5	86 0.2×	45 0.2×	92 0.4×	147 0.8×	24 0.2×	6	790
Stefano G. Daniele United States	9	23 0.1×	60 0.2×	153 0.6×	166 0.9×	18 0.1×	13	557
Moin U. Fareed United States	14	27 0.1×	144 0.5×	41 0.2×	479 2.7×	160 1.2×	16	975
Carla Enrica Gallenga Italy	18	65 0.2×	45 0.2×	52 0.2×	251 1.4×	31 0.2×	36	756
Monica Verma–Gandhu Canada	8	43 0.1×	59 0.2×	70 0.3×	134 0.8×	15 0.1×	9	777
Verena Prokosch Germany	18	43 0.1×	54 0.2×	29 0.1×	307 1.7×	44 0.3×	79	851
Lisa Agatea Italy	10	13 0.0×	556 1.9×	107 0.4×	1.0k 5.8×	304 2.2×	12	1.6k

Countries citing papers authored by Matthew Leoni

Since Specialization

Citations

This map shows the geographic impact of Matthew Leoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Leoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Leoni more than expected).

Fields of papers citing papers by Matthew Leoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Leoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Leoni. The network helps show where Matthew Leoni may publish in the future.

Co-authorship network of co-authors of Matthew Leoni

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Leoni. A scholar is included among the top collaborators of Matthew Leoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Leoni. Matthew Leoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Horan, W. P., Amir H Kalali, Stephen K. Brannan, et al.. (2025). Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decades of Clinical Trials. Schizophrenia Bulletin. 51(2). 262–273. 3 indexed citations

Fernandez, Hubert H., Stuart Isaacson, Robert A. Hauser, et al.. (2025). Efficacy and Safety of Tavapadon, an Orally Administered, Once-daily, Selective D1/D5 Partial Dopamine Agonist, Adjunctive to Levodopa for Treatment of Parkinson’s Disease with Motor Fluctuations (S37.003). Neurology. 104(7_Supplement_1). 1 indexed citations

Takahashi, Koji, Meera Tugnait, Ih Chang, et al.. (2024). EMPOWERing the Next-Generation: A Phase 2 Program to Evaluate Emraclidine, a Selective M4 Positive Allosteric Modulator (PAM), for the Treatment of Schizophrenia. CNS Spectrums. 29(5). 495–495.

Krystal, John H., John M. Kane, Christoph U. Correll, et al.. (2022). Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. The Lancet. 400(10369). 2210–2220. 77 indexed citations

Navaratnam, Prakash, Steve Arcona, Howard S. Frıedman, Matthew Leoni, & Rahul Sasané. (2022). Levodopa treatment patterns in Parkinson’s disease: A retrospective chart review. Clinical Parkinsonism & Related Disorders. 6. 100135–100135. 4 indexed citations

Whitmore, Laura M., et al.. (2022). Ensuring the Continuity of Data Collection in a Focal Epilepsy Clinical Trial During the COVID-19 Pandemic (P2-8.007). Neurology. 98(18_supplement). 1 indexed citations

Duvvuri, Sridhar, Matthew Leoni, Ih Chang, et al.. (2022). Pharmacokinetics, Pharmacodynamics, and Safety of the Highly Selective Dopamine D1/D5 Agonist Tavapadon: Summary of Phase 1 Clinical Studies (P10-11.001). Neurology. 98(18_supplement). 2 indexed citations

Navaratnam, Prakash, et al.. (2021). Natural history and patterns of treatment change in Parkinson’s disease: A retrospective chart review. Clinical Parkinsonism & Related Disorders. 6. 100125–100125. 4 indexed citations

Johnsrud, Michael, Kristin M. Richards, Steve Arcona, Rahul Sasané, & Matthew Leoni. (2021). An assessment of Parkinson’s disease medication treatment patterns in the Medicaid population. Clinical Parkinsonism & Related Disorders. 5. 100109–100109. 5 indexed citations

10.

Weiss, Jonathan, Linda Stein Gold, Matthew Leoni, et al.. (2015). Customized Single-agent Therapy Management of Severe Inflammatory Acne: A Randomized, Double-blind, Parallel-group, Controlled Study of a New Treatment--Adapalene 0.3%-Benzoyl Peroxide 2.5% Gel.. PubMed. 14(12). 1427–35. 14 indexed citations

11.

Jm, Jackson, Joseph F. Fowler, Angela Moore, et al.. (2014). Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea.. PubMed. 13(6). 699–704. 20 indexed citations

12.

Tan, Jerry, Hong Liu, William D. James, & Matthew Leoni. (2014). Reliability of Clinician Erythema Assessment grading scale. Journal of the American Academy of Dermatology. 71(4). 760–763. 88 indexed citations

13.

Moore, Angela, Steven Kempers, George J. Murakawa, et al.. (2014). Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study.. PubMed. 13(1). 56–61. 69 indexed citations

14.

Fowler, Joseph F., Jerry Tan, J. Mark Jackson, et al.. (2014). Treatment of facial erythema in patients with rosacea with topical brimonidine tartrate: correlation of patient satisfaction with standard clinical endpoints of improvement of facial erythema. Journal of the European Academy of Dermatology and Venereology. 29(3). 474–481. 13 indexed citations

15.

Fowler, Joseph F., Michael Jarratt, Angela Moore, et al.. (2011). Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. British Journal of Dermatology. 166(3). 633–641. 107 indexed citations

16.

Kaufman, Jonathan L., Rubén Niesvizky, Edward A. Stadtmauer, et al.. (2008). First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma. Blood. 112(11). 3697–3697. 10 indexed citations

17.

Browne, Kevin D., Matthew Leoni, Akira Iwata, Xiaohan Chen, & Douglas H. Smith. (2004). Acute treatment with MgSO₄ attenuates long‐term hippocampal tissue loss after brain trauma in the rat. Journal of Neuroscience Research. 77(6). 878–883. 19 indexed citations

18.

Smith, Douglas H., Masahiro Nonaka, Reid Miller, et al.. (2000). Immediate coma following inertial brain injury dependent on axonal damage in the brainstem. Journal of neurosurgery. 93(2). 315–322. 168 indexed citations

19.

Leoni, Matthew, et al.. (2000). NPS 1506 Attenuates Cognitive Dysfunction and Hippocampal Neuron Death Following Brain Trauma in the Rat. Experimental Neurology. 166(2). 442–449. 18 indexed citations

20.

Nonaka, Masahiro, Xiaohan Chen, Jean E.S. Pierce, et al.. (1999). Prolonged Activation of NF-κB Following Traumatic Brain Injury in Rats. Journal of Neurotrauma. 16(11). 1023–1034. 153 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact